Formoterol fumarate

• Bronchodilator Agents
• Sympathomimetic
• ATC:R03AC13

• Foradil
• Formoterol [Usan:Inn]
• Formoterol fumarate
• Formoterolum [Inn-Latin]
• Oxeze
• Oxeze Turbuhaler
• Oxeze Turbuhaler Foradil

• No information avaliable

C₁₉H₂₄N₂O₄

http://www.rxlist.com/cgi/generic/foradil.htm

Formoterol_fumarate FDA

Formoterol_fumarate MSDS

No information avaliable

344.405 g/mol

No information avaliable

Slightly (as fumarate salt)

Solid

2.083

Metered-dose (aerosol); Powder

For use as long-term maintenance treatment of asthma in patients 6 years of age and older with reversible obstructive airways disease, including patients with symptoms of nocturnal asthma, who are using optimal corticosteroid treatment and experiencing regular or frequent breakthrough symptoms requiring use of a short-acting bronchodilator.

Formoterol is a long-acting selective beta2-adrenergic receptor agonist (beta2-agonist). Inhaled formoterol fumarate acts locally in the lung as a bronchodilator. In vitro studies have shown that formoterol has more than 200-fold greater agonist activity at beta2-receptors than at beta1- receptors. Although beta2-receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-receptors are the predominant receptors in the heart, there are also beta2-receptors in the human heart comprising 10%-50% of the total beta-adrenergic receptors. The precise function of these receptors has not been established, but they raise the possibility that even highly selective beta2- agonists may have cardiac effects.

Rapidly absorbed into plasma following administration by oral inhalation. It is likely that the majority of the inhaled formoterol delivered is swallowed and then absorbed from the gastrointestinal tract.

An overdosage is likely to lead to effects that are typical of ß2-adrenergic stimulants: nausea, vomiting, headache, tremor, somnolence, palpitations, tachycardia, ventricular arrhythmias, metabolic acidosis, hypokalemia, hyperglycemia.

Humans and other mammals